enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment
enVVeno Medical (Nasdaq: NVNO) has announced its participation in the Virtual Investor Closing Bell Series scheduled for Tuesday, April 22nd, 2025 at 4:00 PM ET. Robert Berman, the company's Chief Executive Officer, will lead the presentation.
During the live webcast, Berman will provide a corporate overview and discuss enVVeno's innovative portfolio, including their VenoValve® and enVVe® technologies - novel implantable replacement venous valve solutions designed for treating severe deep venous CVI. The event will feature a moderated discussion followed by a live Q&A session.
Investors can access the live video webcast through the Events page on www.envveno.com. A replay will be available two hours after the live event and remain accessible for 90 days.
enVVeno Medical (Nasdaq: NVNO) ha annunciato la sua partecipazione alla Virtual Investor Closing Bell Series, in programma per martedì 22 aprile 2025 alle ore 16:00 ET. Robert Berman, Amministratore Delegato dell'azienda, guiderà la presentazione.
Durante la diretta webcast, Berman fornirà una panoramica aziendale e illustrerà il portafoglio innovativo di enVVeno, incluse le tecnologie VenoValve® e enVVe® - nuove soluzioni impiantabili per la sostituzione della valvola venosa, progettate per il trattamento della grave insufficienza venosa profonda cronica (CVI). L'evento prevede una discussione moderata seguita da una sessione di domande e risposte in diretta.
Gli investitori potranno accedere alla diretta video tramite la pagina Eventi su www.envveno.com. La replica sarà disponibile due ore dopo l'evento e resterà accessibile per 90 giorni.
enVVeno Medical (Nasdaq: NVNO) ha anunciado su participación en la Virtual Investor Closing Bell Series programada para el martes 22 de abril de 2025 a las 4:00 PM ET. Robert Berman, CEO de la compañía, dirigirá la presentación.
Durante la transmisión en vivo, Berman ofrecerá una visión general corporativa y hablará sobre el innovador portafolio de enVVeno, incluyendo sus tecnologías VenoValve® y enVVe® - novedosas soluciones implantables para reemplazo de válvulas venosas diseñadas para tratar la insuficiencia venosa profunda crónica (CVI) severa. El evento incluirá una discusión moderada seguida de una sesión de preguntas y respuestas en vivo.
Los inversores podrán acceder a la transmisión en vivo a través de la página de Eventos en www.envveno.com. La repetición estará disponible dos horas después del evento en vivo y permanecerá accesible durante 90 días.
enVVeno Medical(나스닥: NVNO)는 2025년 4월 22일 화요일 오후 4시(동부 시간)에 예정된 Virtual Investor Closing Bell Series에 참여한다고 발표했습니다. 회사의 CEO인 로버트 버먼이 발표를 진행할 예정입니다.
라이브 웹캐스트 동안 버먼은 회사 개요를 제공하고, 심각한 만성 정맥 기능 부전(CVI) 치료를 위해 설계된 혁신적인 이식형 정맥 판막 대체 솔루션인 VenoValve® 및 enVVe® 기술을 포함한 enVVeno의 혁신적인 포트폴리오에 대해 설명할 것입니다. 행사에는 중재된 토론과 라이브 질의응답 세션이 포함됩니다.
투자자들은 www.envveno.com의 이벤트 페이지를 통해 라이브 비디오 웹캐스트에 접속할 수 있습니다. 생중계 종료 2시간 후부터 재방송이 제공되며 90일간 시청할 수 있습니다.
enVVeno Medical (Nasdaq : NVNO) a annoncé sa participation à la Virtual Investor Closing Bell Series prévue le mardi 22 avril 2025 à 16h00 ET. Robert Berman, le PDG de la société, dirigera la présentation.
Lors de la diffusion en direct, Berman présentera un aperçu de l'entreprise et discutera du portefeuille innovant d’enVVeno, incluant les technologies VenoValve® et enVVe® – des solutions implantables novatrices de remplacement des valves veineuses conçues pour traiter l'insuffisance veineuse chronique profonde sévère (CVI). L'événement comprendra une discussion modérée suivie d'une séance de questions-réponses en direct.
Les investisseurs pourront accéder à la diffusion vidéo en direct via la page Événements sur www.envveno.com. Un replay sera disponible deux heures après l'événement en direct et restera accessible pendant 90 jours.
enVVeno Medical (Nasdaq: NVNO) hat seine Teilnahme an der Virtual Investor Closing Bell Series angekündigt, die am Dienstag, den 22. April 2025 um 16:00 Uhr ET stattfindet. Robert Berman, der CEO des Unternehmens, wird die Präsentation leiten.
Während des Live-Webcasts wird Berman einen Unternehmensüberblick geben und das innovative Portfolio von enVVeno vorstellen, einschließlich der Technologien VenoValve® und enVVe® – neuartige implantierbare venöse Klappenersatzlösungen zur Behandlung schwerer chronischer tiefer Venenerkrankungen (CVI). Die Veranstaltung umfasst eine moderierte Diskussion, gefolgt von einer Live-Fragerunde.
Investoren können über die Veranstaltungsseite auf www.envveno.com auf den Live-Video-Webcast zugreifen. Eine Wiederholung ist zwei Stunden nach der Live-Veranstaltung verfügbar und bleibt 90 Tage lang zugänglich.
- None.
- None.
Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Tuesday, April 22nd at 4:00 PM ET
IRVINE, CA / ACCESS Newswire / April 16, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in the Virtual Investor Closing Bell Series on Tuesday, April 22, 2025 at 4:00 PM ET.
As part of the event, Mr. Berman will provide a corporate overview and discuss the Company's portfolio of novel implantable replacement venous valve technologies, the VenoValve® and enVVe®, for the treatment of severe deep venous CVI. In addition to the moderated discussion, there will be a live question and answer session. Mr. Berman will answer as many questions as possible in the time allowed.
A live video webcast of the presentation will be available on the Events page of the Company's website (www.envveno.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775
MEDIA CONTACT:
Glenn Silver, FINN Partners
Glenn.Silver@finnpartners.com
(973) 818-8198
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire
FAQ
When is enVVeno Medical's (NVNO) Virtual Investor Closing Bell presentation?
What technologies will be discussed during NVNO's investor presentation?
How long will NVNO's investor presentation replay be available?
Where can investors watch NVNO's Virtual Investor Closing Bell presentation?
What format will NVNO's Virtual Investor Closing Bell event follow?
